Acarix AB (OSTO:ACARIX) Cyclically Adjusted FCF per Share: kr-0.58 (As of Mar. 2026)


OSTO:ACARIX Acarix AB OSTO:ACARIX
44 GF Score
Price kr0.25
GF Value kr0.23
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Acarix AB Cyclically Adjusted FCF per Share?

Acarix AB OSTO:ACARIX -1.17% 44 Cyclically Adjusted FCF per Share is kr-0.58 as of Mar. 2026. GuruFocus rates OSTO:ACARIX with a GF Score™ of 44/100 and a GF Value™ of kr0.23 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Acarix AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr0.001. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-0.58 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-12), Acarix AB's current stock price is kr0.254. Acarix AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-0.58. Acarix AB's Cyclically Adjusted Price-to-FCF of today is .


Acarix AB  (OSTO:ACARIX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Acarix AB Cyclically Adjusted FCF per Share Related Terms


Acarix AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Acarix AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acarix AB Cyclically Adjusted FCF per Share Chart

Acarix AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.61

Acarix AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.63 -0.62 -0.61 -0.58

OSTO:ACARIX vs ABT, SYK, MDT: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Acarix AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acarix AB Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Acarix AB's Cyclically Adjusted Price-to-FCF falls into.


OSTO:ACARIX
44GF Score
Acarix AB OSTO:ACARIX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acarix AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Acarix AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.001/133.5600*133.5600
=0.001

Current CPI (Mar. 2026) = 133.5600.

Acarix AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.188 101.019 -0.249
201609 -0.227 101.138 -0.300
201612 -0.117 102.022 -0.153
201703 -0.360 102.022 -0.471
201706 -0.227 102.752 -0.295
201709 -0.142 103.279 -0.184
201712 -0.126 103.793 -0.162
201803 -0.186 103.962 -0.239
201806 -0.183 104.875 -0.233
201809 -0.219 105.679 -0.277
201812 -0.172 105.912 -0.217
201903 -0.382 105.886 -0.482
201906 -0.359 106.742 -0.449
201909 -0.365 107.214 -0.455
201912 -0.191 107.766 -0.237
202003 -0.130 106.563 -0.163
202006 -0.132 107.498 -0.164
202009 -0.060 107.635 -0.074
202012 -0.068 108.296 -0.084
202103 -0.053 108.360 -0.065
202106 -0.091 108.928 -0.112
202109 -0.060 110.338 -0.073
202112 -0.085 112.486 -0.101
202203 -0.058 114.825 -0.067
202206 -0.068 118.384 -0.077
202209 -0.086 122.296 -0.094
202212 -0.062 126.365 -0.066
202303 -0.055 127.042 -0.058
202306 -0.029 129.407 -0.030
202309 -0.037 130.224 -0.038
202312 -0.036 131.912 -0.036
202403 -0.024 132.205 -0.024
202406 -0.018 132.716 -0.018
202409 -0.014 132.304 -0.014
202412 -0.016 132.987 -0.016
202503 -0.010 132.825 -0.010
202506 -0.012 133.699 -0.012
202509 -0.007 133.480 -0.007
202512 -0.015 133.390 -0.015
202603 0.001 133.560 0.001

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-0.58 mean?
Acarix AB (OSTO:ACARIX) has a Cyclically Adjusted FCF per Share of kr-0.58 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Acarix AB and its competitors.
Is Acarix AB's Cyclically Adjusted FCF per Share too high?
Acarix AB's current Cyclically Adjusted FCF per Share is kr-0.58. Overall, Acarix AB has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Cyclically Adjusted FCF per Share compare to ABT and SYK?
Acarix AB's Cyclically Adjusted FCF per Share of kr-0.58 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Acarix AB and its competitors. Acarix AB's current Cyclically Adjusted FCF per Share is kr-0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (OSTO:ACARIX) is currently considered Fairly Valued. The stock's GF Value™ is kr0.23, compared to a current price of kr0.25 — trading 10.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-0.58. Acarix AB's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Acarix AB (OSTO:ACARIX), the current Cyclically Adjusted FCF per Share is kr-0.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acarix AB (OSTO:ACARIX) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued. The current stock price of kr0.25 is trading 10.4% above its estimated GF Value™ of kr0.23. GuruFocus considers Acarix AB to be Fairly Valued.

Key valuation signals for OSTO:ACARIX:

  • Cyclically Adjusted FCF per Share: kr-0.58
  • GF Value™: kr0.23 vs. price of kr0.25 (10.4% above fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the OSTO:ACARIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Acarix AB Business Description

Other Exchanges ACIXF:USA
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
44GF Score

Get the complete analysis for OSTO:ACARIX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.25
Price
kr0.23
GF Value